RxDoctor Payments Data

Sharon Pagdilao, NP

Nurse Practitioner · Colorado Springs, CONPI 1902537962

Payments from drug & device makers

$1,160in general payments, 2019–2025

Across 49 payments — averaging $23.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Scilex Pharmaceuticals Inc.$315
  • Collegium Pharmaceutical, Inc.$263
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$212
  • AbbVie$193
  • Averitas Pharma Inc.$49
  • Boston Scientific$47
  • plus $81 from 3 others

What the payments were for

  • Food & beverage$99085%
  • Education$17015%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,160 in reported general payments places this provider in the 85th percentile of 1,384 nurse practitioner providers in Colorado.

See all nurse practitioner providers in Colorado

Medicare billing

Part B allowed, 2024
$65,660
Medicare patients
50
Services billed
656

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RelistorMethylnaltrexone Bromide12$68,488
BelbucaBuprenorphine Hcl39$30,404
NucyntaTapentadol Hcl15$22,737
Buprenorphine62$13,553
MovantikNaloxegol Oxalate15$6,174
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen115$4,164
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen103$3,885
Oxycodone Hcl121$2,656
Celecoxib27$1,700
Cyclobenzaprine Hcl74$1,302
Lidocaine18$1,251
Tramadol Hcl44$1,240
Tramadol Hcl ErTramadol Hcl22$1,111
Naloxone Hcl17$993
Ondansetron OdtOndansetron20$933

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$212$68,48812 claims
Collegium Pharmaceutical, Inc.Belbuca, Nucynta$263$53,14154 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,384 nurse practitioner providers in Colorado.

Other nurse practitioner in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →